Recently, a novel CD38 x CD3 BTCE with Fc domain engineered to limit Fcγ receptor binding and non-specific T-cell activation, is currently being investigated in a Phase 1 study for patients with r/r T-ALL and AML (NCT05038644) [146]. Here, CD38 is linked to acute myeloid leukemia.